Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Biologicals » Biologicals-Cells-Human Neural Progenitor, Alzheimer's » Axol Alzheimer's Disease Neural Progenitor Cells, Human, Presenilin-1 Mutation L286V (AD hNPC), Frozen Cells

Axol Alzheimer's Disease Neural Progenitor Cells, Human, Presenilin-1 Mutation L286V (AD
hNPC), Frozen Cells


  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.


Alzheimers disease is an incurable, fatal neurodegenerative disorder now affecting over 24 million people worldwide and that is predicted to reach 100 million by 2050. Without an effective treatment, our aging society will soon face an Alzheimers disease epidemic that will ultimately lead to social catastrophe and saddle heavy economic burden on our healthcare systems.
Catalog #ax0112
Alzheimer's research will provide insights which will help to prevent and cure the disease. Up to now, the research has heavily relied upon genetically modified animal models which are time consuming and expensive to produce, maintain and experiment on. Our human iPS cell-derived AD hNPCs provide scientists an affordable and easily accessible platform for building their own human cellular models of Alzheimer's disease in a disease-relevant genetic and tissue context.
Advantages of Axol hNPCs Human cells derived from diagnosed Alzheimer's disease patients
Available in industrial quantity
High purity neural progenitor population
Ready-made and easy to differentiate
No reprogramming and differentiation needed
Robust enough to undergo genetic manipulation
Supplied with extensive functional and molecular characterization data
Capable of differentiating to a spectrum of cortical excitatory and inhibitory neurons
Remain viable in culture for months to facilitate reproducible and long term studies
Cells from multiple donors are available for purchase allowing data comparison among biological replicates
Applications Studying AD pathogenesis at cellular level
Studying neural network formation and signal transmission in AD neural culture
Neurotoxicity testing
Preclinical drug efficacy testing
Specifications Quantity: 2 million expandable cells per vial
Presentation: Cells are provided cryopreserved in 1 ml of freezing medium
Storage Condition: Liquid nitrogen
Growth Properties: Adherent 
Donor Age38yr
Clinical AD DiagnosisYes
GenotypePresenilin-1 Mutation L286V
Starting MaterialDermal Fibroblasts
Reprogramming MethodEpisomal Plasmid
Neural Induction MethodMonolayer and Chemically-defined medium
Size2 Million cells
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

External Links